Triaziquone

Triaziquone is an antimalarial drug used to treat malaria caused by Plasmodium falciparum. It is usually given in combination with other antimalarials. Triaziquone works by inhibiting the growth of the malaria parasite in the body. It is usually taken once a day for three days. Side effects can include nausea, headache, dizziness, and abdominal pain.

Triaziquone is a drug used in chemotherapy [Wikipedia]. It belongs to a class of compounds called aziridinylbenzoquinones [Drugbank online]. 

Here's a summary of Triaziquone:

• Function: Alkylating agent [Wikipedia]. This means it can transfer alkyl groups to other molecules. In the case of cancer cells, this can damage their DNA and RNA, ultimately leading to cell death.
• Mechanism of action: Inhibits DNA and RNA synthesis [MDPI]. It is thought to work by alkylating cellular components, which disrupts essential cellular processes.
• Development: First synthesized in 1958 [MDPI]. Introduced clinically for the treatment of a number of cancers in the 1960s, but it is no longer widely used today.